New combo therapy shows promise for aggressive lung cancer
NCT ID NCT05092412
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tested a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The treatment combines low-dose radiation, an immunotherapy drug (durvalumab), and standard chemotherapy. The goal was to see if this combination could help control the cancer longer. The study enrolled 30 adults and is no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610044, China
Conditions
Explore the condition pages connected to this study.